文献速递药物相互作用治疗药物监测与药物基因组学

利用药物遗传学数据对CYP2C19底物BMS-823778进行基于生理的药代动力学建模

Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.
PubMed 文献 · Br J Clin Pharmacol · 2018-04-10

本研究基于现有临床数据构建并验证了BMS-823778的PBPK模型,模拟预测不同CYP2C19和UGT1A4基因型虚拟人群中的PK及与强CYP3A4抑制剂的DDI。模型准确再现了不同人群的观察PK及CYP2C19基因型间暴露差异,提示UGT1A4可能是CYP2C19慢代谢者的重要清除途径,且与伊曲康唑的DDI可能取决于CYP2C19和UGT1A4基因型。

要点

  • PBPK模型可准确预测不同CYP2C19表型人群的BMS-823778暴露。
  • CYP2C19慢代谢且UGT1A4无功能者暴露更高,UGT1A4可能是重要清除途径。
  • 与伊曲康唑的DDI程度可能取决于CYP2C19和UGT1A4基因型。

核心结论

  • 基于临床数据构建的PBPK模型能准确预测不同CYP2C19表型人群的BMS-823778人体PK。
  • 模拟提示UGT1A4可能是CYP2C19慢代谢者的重要清除途径。
  • 与伊曲康唑的DDI可能取决于CYP2C19和UGT1A4基因型。

研究设计与样本

  • 基于生理的药代动力学(PBPK)建模研究,使用现有临床数据构建并验证模型。
  • 验证后的模型在具有多种CYP2C19和UGT1A4基因型的虚拟人群中模拟PK及DDI。

主要发现

  • 验证的PBPK模型准确再现了不同人群的观察PK。
  • 模型能捕捉不同CYP2C19基因型受试者间的暴露差异。
  • CYP2C19慢代谢且UGT1A4无活性者的BMS-823778暴露高于UGT1A4功能正常者。
  • 在CYP2C19或UGT1A4野生型受试者中预测与伊曲康唑发生中度DDI。
  • 在CYP2C19和UGT1A4均无功能受试者中,BMS-823778与伊曲康唑合用时预测发生显著DDI。

临床怎么用

  • 对CYP2C19慢代谢且UGT1A4无功能患者,合用强CYP3A4抑制剂时需关注暴露升高及DDI风险。
  • CYP2C19和UGT1A4基因型可能有助于评估BMS-823778与伊曲康唑的DDI风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Previous studies demonstrated direct correlation between CYP2C19 genotype and BMS-823778 clearance in healthy volunteers. The objective of the present study was to develop a physiologically-based pharmacokinetic (PBPK) model for BMS-823778 and use the model to predict PK and drug-drug interaction (DDI) in virtual populations with multiple polymorphic genes. METHODS: The PBPK model was built and verified using existing clinical data. The verified model was simulated to predict PK of BMS-823778 and significance of DDI with a strong CYP3A4 inhibitor in subjects with various CYP2C19 and UGT1A4 genotypes. RESULTS: The verified PBPK model of BMS-823778 accurately recovered observed PK in different populations. In addition, the model was able to capture the exposure differences between subjects with different CYP2C19 genotypes. PK simulation indicated higher exposures of BMS-823778 in CYP2C19 poor metabolizers who were also devoid of UGT1A4 activity, compared to those with normal UGT1A4 functionality. Moderate DDI with itraconazole was predicted in subjects with wild-type CYP2C19 or UGT1A4. However, in subjects without CYP2C19 or UGT1A4 functionality, significant DDI was predicted when BMS-823778 was coadministered with itraconazole. CONCLUSIONS: A PBPK model was developed using clinical data that accurately predicted human PK in different population with various CYP2C19 phenotypes. Simulations with the verified PBPK model indicated that UGT1A4 was probably an important clearance pathway in CYP2C19 poor metabolizers. DDI with itraconazole is likely to be dependent on the genotypes of CYP2C19 and UGT1A4.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Gong J, Iacono L, Iyer RA, et al. Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data. Br J Clin Pharmacol. 2018. PMID: 29469197. doi:10.1111/bcp.13565

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。